학술논문
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF- [beta], in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
Brief Communication
transforming growth factor
Brief Communication
transforming growth factor
Document Type
Report
Author
Source
The Oncologist. February 2023, Vol. 28 Issue 2, pS124, 4 p.
Subject
Language
English
ISSN
1083-7159
Abstract
Introduction Colorectal cancer (CRC) is a heterogeneous and complex disease with widely variable clinical outcomes. (1) Although recent advances in systemic therapy for metastatic CRC (mCRC) have improved outcomes for [...]
Colorectal cancer (CRC) is a heterogeneous and complex disease with limited treatment options. Targeting transforming growth factor [beta] (TGF-[beta]) and programmed death ligand 1 pathways may enhance antitumor efficacy. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-[beta] receptor II (a TGF-[beta] "trap") fused to a human IgG1 monoclonal antibody blocking programmed cell death ligand 1. We report results from an expansion cohort of a phase I study (NCT02517398) in patients with heavily pretreated advanced CRC treated with bintrafusp alfa. As of May 15, 2020, 32 patients with advanced CRC had received bintrafusp alfa for a median duration of 7.1 weeks. The objective response rate was 3.1% and the disease control rate was 6.3% (1 partial response, 1 stable disease); 2 patients were not evaluable. The safety profile was consistent with previously reported data. Key words: colorectal cancer; bintrafusp alfa; phase I.
Colorectal cancer (CRC) is a heterogeneous and complex disease with limited treatment options. Targeting transforming growth factor [beta] (TGF-[beta]) and programmed death ligand 1 pathways may enhance antitumor efficacy. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-[beta] receptor II (a TGF-[beta] "trap") fused to a human IgG1 monoclonal antibody blocking programmed cell death ligand 1. We report results from an expansion cohort of a phase I study (NCT02517398) in patients with heavily pretreated advanced CRC treated with bintrafusp alfa. As of May 15, 2020, 32 patients with advanced CRC had received bintrafusp alfa for a median duration of 7.1 weeks. The objective response rate was 3.1% and the disease control rate was 6.3% (1 partial response, 1 stable disease); 2 patients were not evaluable. The safety profile was consistent with previously reported data. Key words: colorectal cancer; bintrafusp alfa; phase I.